Publicaciones en las que colabora con María Ángel García Chaves (20)

2023

  1. Interferon-Alpha Decreases Cancer Stem Cell Properties and Modulates Exosomes in Malignant Melanoma

    Cancers, Vol. 15, Núm. 14

2020

  1. Uncovering tumour heterogeneity through PKR and nc886 analysis in metastatic colon cancer patients treated with 5-FU-based chemotherapy

    Cancers, Vol. 12, Núm. 2

2019

  1. Melanoma cancer stem-like cells: Optimization method for culture, enrichment and maintenance

    Tissue and Cell, Vol. 60, pp. 48-59

  2. Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Mesenchymal stem cell's secretome promotes selective enrichment of cancer stem-like cells with specific cytogenetic profile

    Cancer Letters, Vol. 429, pp. 78-88

2017

  1. A formulation of pancreatic pro-enzymes provides potent anti-tumour efficacy: A pilot study focused on pancreatic and ovarian cancer

    Scientific Reports, Vol. 7, Núm. 1

  2. Clinical and therapeutic potential of protein kinase PKR in cancer and metabolism

    Expert Reviews in Molecular Medicine, Vol. 19

  3. Validation of suitable normalizers for miR expression patterns analysis covering tumour heterogeneity

    Scientific Reports, Vol. 7

2016

  1. Polymers, scaffolds and bioactive molecules with therapeutic properties in osteochondral pathologies: what’s new?

    Expert Opinion on Therapeutic Patents, Vol. 26, Núm. 8, pp. 877-890

2015

  1. 5-Fluorouracil derivatives: A patent review (2012 - 2014)

    Expert Opinion on Therapeutic Patents, Vol. 25, Núm. 10, pp. 1131-1144

  2. Erratum to "Cardiomyogenic differentiation potential of human endothelial progenitor cells isolated from patients with myocardial infarction" (Cytotherapy 2014;16:1229-1237)

    Cytotherapy

2014

  1. Cardiomyogenic differentiation potential of human endothelial progenitor cells isolated from patients with myocardial infarction

    Cytotherapy, Vol. 16, Núm. 9, pp. 1229-1237

  2. EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer

    Oncotarget, Vol. 5, Núm. 17, pp. 7486-7497

  3. HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound

    Oncotarget, Vol. 5, Núm. 11, pp. 3590-3606

  4. The impact of PKR activation: From neurodegeneration to cancer

    FASEB Journal, Vol. 28, Núm. 5, pp. 1965-1974

2013

  1. Bozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis and synergizes with IFNα triggering apoptosis, autophagy and senescence

    Drug Design, Development and Therapy, Vol. 7, pp. 1301-1313

  2. How can nanotechnology help to repair the body? Advances in cardiac, skin, bone, cartilage and nerve tissue regeneration

    Materials, Vol. 6, Núm. 4, pp. 1333-1359

  3. In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation

    Cellular Oncology, Vol. 36, Núm. 4, pp. 289-301

2012

  1. Functionalized nanostructures with application in regenerative medicine

    International Journal of Molecular Sciences, Vol. 13, Núm. 3, pp. 3847-3886

  2. Role of cancer stem cells of breast, colon, and melanoma tumors in the response to antitumor therapy

    Stem Cells and Cancer Stem Cells, Volume 3: Stem Cells and Cancer Stem Cells, Therapeutic Applications in Disease and Injury: Volume 3 (Springer Netherlands), pp. 157-171